Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 16/20 | 0.56 |
| ▸ | UBE2M | P61081 | 15/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CASR | P41180 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590485 | 0.92 | HCRTR1 (0.55) | DCUN1D1UBE2MALDH1A1LMNAHSD17B10 | |
| SCHEMBL549026 | 0.83 | DCUN1D1 (0.64) | DCUN1D1UBE2MCASREPHX2 | |
| SCHEMBL5126613 | 0.83 | DCUN1D1 (0.62) | DCUN1D1UBE2MCASR | |
| SCHEMBL4676983 | 0.82 | CASR (0.63) | DCUN1D1UBE2MCASRMAPT | |
| SCHEMBL549106 | 0.81 | DCUN1D1 (0.60) | DCUN1D1UBE2MCASR | |
| SCHEMBL548245 | 0.80 | DCUN1D1 (0.58) | DCUN1D1UBE2MCASR | |
| SCHEMBL548234 | 0.79 | DCUN1D1 (0.72) | DCUN1D1UBE2MCASR | |
| SCHEMBL548246 | 0.77 | DCUN1D1 (0.55) | DCUN1D1UBE2MCASR | |
| SCHEMBL18640247 | 0.72 | DCUN1D1 (1.00) | DCUN1D1UBE2M | |
| SCHEMBL18640257 | 0.72 | DCUN1D1 (1.00) | DCUN1D1UBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110574-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20110059971-A1 | DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT | IPSEN S.A.S. (FR) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059971-A1 | DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT | SSTR4, SSTR3, SSTR1 | DCUN1D1 3971/4885UBE2M 4777/4885ALDH1A1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.